MétaCan
Menu
Back to cohort
Record W4214740171 · doi:10.1093/neuonc/nou265.2

NT-02 * EARLY TREATMENT OF HER2-AMPLIFIED BRAIN TUMOURS WITH TARGETED NK-92 CELLS AND FOCUSED ULTRASOUND IMPROVES SURVIVAL

2014· article· en· W4214740171 on OpenAlexaff
Ryan Alkins, A. G. Burgess, Giulio Francia, Robert S. Kerbel, Winfried S. Wels, Kullervo Hynynen

Bibliographic record

VenueNeuro-Oncology · 2014
Typearticle
Languageen
FieldMaterials Science
TopicNanoparticle-Based Drug Delivery
Canadian institutionsUniversity of TorontoSunnybrook Health Science Centre
Fundersnot available
KeywordsMedicineBrain metastasisCancer researchMicrobubblesBreast cancerRadiation therapyMetastasisPathologyCancerInternal medicineUltrasound

Abstract

fetched live from OpenAlex

Malignant brain tumors have a dismal prognosis. Microscopic and often macroscopic residual remain after surgical resection, necessitating adjuvant chemo- and radiotherapy. Many intravenously delivered chemotherapeutic agents are hindered by the cerebral capillary endothelium and blood brain barrier (BBB), either due to their size, lipophilicity, or their interaction with efflux channels, resulting in modest treatment efficacy. Both those chemotherapeutic agents that cross the BBB and radiotherapy result in significant damage to healthy brain tissue. We previously demonstrated that targeted Natural Killer (NK-92) cells could be delivered to focal regions of the brain using a combination of focused ultrasound and Definity microbubbles. Targeted NK cells have advantages over other systemic therapies including their specific cytotoxicity to malignant cells, particularly those expressing the target antigen, in addition to sparing healthy cells and being unaffected by efflux channels. As such, once these cells gain access to the CNS, they can track to malignant tissues without inflicting collateral damage. We investigated whether multiple combined treatments of targeted NK-92 cells and focused ultrasound with microbubbles could slow tumor growth and improve survival in an orthotopic HER2-amplified rodent brain tumor model, using a human breast cancer line as a prototype. The HER2 receptor is expressed by a number of epithelial tumours including breast and glioblastoma. Breast cancers with HER2 amplification are more aggressive, have a higher risk of CNS metastasis, and poorer prognosis. We found that early intensive treatment with targeted NK-92 cells and ultrasound improved survival compared with bi-weekly treatments, or either treatment alone. The intensive treatment paradigm resulted in cure in 50% of subjects. Many tumour proteins could be exploited for targeted therapy with the NK-92 cell line, and combined with the mounting safety evidence for trans-cranial ultrasound, this may soon provide a non-invasive and highly targeted treatment option for patients with brain tumours.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.007

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.013
GPT teacher head0.240
Teacher spread0.227 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2014
Admission routes1
Has abstractyes

Explore more

Same venueNeuro-OncologySame topicNanoparticle-Based Drug DeliveryFrench-language works237,207